Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Diabetes Care|August 20, 2009
No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetesMarkus Walter, Areti Philotheou, François Bonnici, et al.Methods in Enzymology|August 12, 2018
Radical S-Adenosyl-l-Methionine (SAM) Enzyme Involved in the Maturation of the Nitrogenase ClusterLee Rettberg, Kazuki Tanifuji, Andrew Jasniewski, et al.Diabetes Care|October 27, 2004
IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetesEzio Bonifacio, Michael Hummel, Markus Walter, et al.Annals of Internal Medicine|June 3, 2004
Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parentsMichael Hummel, Ezio Bonifacio, Sandra Schmid, et al.Diabetes Care|April 2, 2010
No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetesMarkus Walter, Thomas Kaupper, Kerstin Adler, et al.Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|December 8, 2009
Insertion of heterometals into the NifEN-associated iron-molybdenum cofactor precursorJanice M Yoshizawa, Aaron W Fay, Chi Chung Lee, et al.Dalton Transactions (Cambridge, England : 2003)|March 12, 2010
Formation of a homocitrate-free iron-molybdenum cluster on NifEN: implications for the role of homocitrate in nitrogenase assemblyAaron Wolfe Fay, Michael Aaron Blank, Janice Mariko Yoshizawa, et al.Molecular Metabolism|February 4, 2018
Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled studySandra Hummel, Andreas Beyerlein, Markus Pfirrmann, et al.Blood|December 17, 2009
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patientsBart Keymeulen, Sophie Candon, Samira Fafi-Kremer, et al.The New England Journal of Medicine|June 24, 2005
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetesBart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, et al.Pageof 1